SCHEMBL24257745

SCHEMBL24257745

CCOC(=O)CNC(=O)c1ncc(-c2cnn(-c3ccccc3)c2)c(C)c1OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 5/20 0.42
RIPK2 O43353 1/20 0.42
HPGD P15428 1/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
PPID Q08752 1/20 0.41
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
GAA P10253 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257724 0.94 RIPK2 (0.39) GRM4RIPK2HPGDRAB9ANPC1
SCHEMBL26259966 0.90 ALDH1A1 (0.39) GRM4RIPK2HPGDPPIDKMT2A
SCHEMBL24257538 0.87 KMT2A (0.39) HPGDPPIDKMT2AL3MBTL1MEN1
SCHEMBL24257699 0.87 HPGD (0.44) GRM4HPGDRAB9ANPC1PPID
SCHEMBL24257785 0.86 KMT2A (0.42) PPIDKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL24257499 0.84 GRM4 (0.50) GRM4RIPK2RAB9ANPC1ALDH1A1
SCHEMBL24257514 0.83 ALDH1A1 (0.48) PPIDKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL30453137 0.83 ALDH1A1 (0.48) PPIDKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL30546860 0.83 ALDH1A1 (0.48) PPIDKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL24257594 0.82 IRAK4 (0.38) RIPK2KMT2AL3MBTL1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 GRM4 3161/4885RIPK2 113/4885HPGD 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.